← FDA DRUG APPROVALS

FDA ANDA · ANDA090788

DIDANOSINE

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA090788
TYPE
ANDA
ORIGINAL APPROVAL
2010-04-08
LATEST ACTION
2019-12-06
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Discontinued

Products

DIDANOSINEDiscontinued
DIDANOSINE 400MG · CAPSULE, DELAYED REL PELLETS · ORAL
DIDANOSINEDiscontinued
DIDANOSINE 200MG · CAPSULE, DELAYED REL PELLETS · ORAL
DIDANOSINEDiscontinued
DIDANOSINE 250MG · CAPSULE, DELAYED REL PELLETS · ORAL
DIDANOSINEDiscontinued
DIDANOSINE 125MG · CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2019-12-06Labeling · Supplement 8 · standardAP
2019-12-06Labeling · Supplement 4 · standardAP
2019-12-06Labeling · Supplement 7 · standardAP
2010-04-08OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →